Skip to main content
. 2020 Nov 28;12(12):3553. doi: 10.3390/cancers12123553

Figure 3.

Figure 3

Therapeutic modalities targeting relapse-associated drivers. EZH2i, EZH2 inhibitors; NK, natural killer cell; CAR-NK cell, chimeric antigen receptor-NK cell; CAR-T cell, chimeric antigen receptor-T cell; KMD5i, KMD5 inhibitor; HDACi, histone deacetylase inhibitor; BETi, BET inhibitor; PI3Ki, PI3K inhibitor; Sirti, sirtuin inhibitor.